Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Source: SeekingAlpha
2026-02-24 23:27:52 ET
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call February 24, 2026 4:30 PM EST
Company Participants
Andrew Guggenhime - President & CFO
Grant Pickering - Co-Founder, CEO & Director
James Wassil - Executive VP & COO
Mike Mullette - Chief Commercial Officer
...
Read the full article on Seeking Alpha
For further details see:
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
0.37% G/L:
$60.01 Last:
318,637 Volume:
$59.20 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
